CSPC Pharmaceutical (HKG:1093) obtained approval for a clinical trial of recombinant herpes zoster vaccine from China's National Medical Products Administration.
The indication for the approval is for the prevention of herpes zoster and its complications in adults aged 50 years and above, according to a Thursday filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.